

Supplementary Table 3. Changes in all lipid profiles at baseline and 48 weeks in the TAF group compared to the non-HBV infected control subjects after propensity score matching

Lipid level	TAF (n=45)			Non-HBV-infected control (n=180)		
	Baseline	48 weeks	P-value	Baseline	48 weeks	P-value
TC (mg/dL)	167.8±35.0	178.5±36.0	0.001	169.8±28.5	176.6±31.3	0.002
LDL-C (mg/dL)	107.6±27.7	116.8±32.4	0.006	111.1±28.4	117.4±30.3	0.004
HDL-C (mg/dL)	50.9±15.0	53.0±14.7	0.097	52.6±12.3	54.4±13.8	0.007
TG (mg/dL)	116.9±109.7	126.1±104.1	0.201	121.0±71.9	111.4±63.8	0.019
TC/HDL ratio	3.5±1.1	3.5±1.0	0.706	3.4±0.9	3.4±0.9	0.572
LDL/HDL ratio	2.3±0.8	2.3±0.9	0.337	2.2±0.8	2.3±0.8	0.225

Values are presented as mean±standard deviation.

TAF, tenofovir alafenamide; HBV, hepatitis B virus; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride.